6876.TWO LAUNXP Biomedical Co., Ltd

Healthcare Biotechnology Taiwan OTC Exchange
12.60 TWD
Close of Nov 6, 2026
9.09 25.45
Market cap
TWD 889M
P/E
-
P/B
2.47x
ROE
-75.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is 6876.TWO undervalued?

Graham number

The Graham number of LAUNXP Biomedical Co., Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LAUNXP Biomedical Co., Ltd fundamental analysis

No fundamental analysis for LAUNXP Biomedical Co., Ltd yet.

LAUNXP Biomedical Co., Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LAUNXP Biomedical Co., Ltd

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.

Full company profile